Marginal Zone Lymphoma — Trials

Marginal Zone Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

407 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 111
Recruiting: 62
Ph III recruiting: 2
Growth YoY: —
Industry share: 22%
Top sponsor: City of Hope Medical Center
Termination share: 38.9%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (79)

clinicaltrialsPublishedShowing 51–100 of 182 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03028103	Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients	completed	Phase 1	32	Epizyme, Inc.INDUSTRY	1	Jun 26, 2023	clinicaltrials
NCT03364231	Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma	completed	Phase 2	21	TG Therapeutics, Inc.INDUSTRY